“…Abraxane significantly increases the compliance of patients (Yardley, ) However, Abraxane may also cause neurotoxicity (Sahoo & Kumar, ). In order to obtain better clinical use of PTX, many PTX delivery systems have been developed and investigated, including micelles (Han et al, ; Luo, Han, Xu, Chen, & Zhang, ), nanoparticles (Jiang et al, ; Wang et al, ; Xiang et al, ; Xin et al, ), liposomes (Hong et al, ; Monteiro et al, ; Wang et al, ), PTX prodrugs (Han et al, ; Jiang et al, ; Jiang et al, ; Luo et al, ; Tam, Gao, & Kwon, ), and so on. Among these PTX delivery systems, PTX prodrugs, especially targeting peptide‐PTX conjugates (Bianchi et al, ; Colombo et al, ; Dal Corso et al, ; Zanella et al, ), achieved great attention because conjugating targeting peptide onto PTX can not only increase the water solubility of PTX, but also endow the conjugate with the capability of targeting tumor cells by ligand–receptor interactions.…”